SCHEMBL8263368

SCHEMBL8263368

O=C1/C(=N\c2cccc3ccccc23)c2ccccc2N1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GALR3 O60755 2/20 0.53
▸ HTR4 Q13639 1/20 0.53
▸ MAPT P10636 8/20 0.50
▸ KMT2A Q03164 8/20 0.50
▸ MEN1 O00255 4/20 0.50
▸ ALDH1A1 P00352 6/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.49
▸ CES2 O00748 1/20 0.49
▸ BCHE P06276 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ CES1 P23141 1/20 0.49
▸ POLB P06746 2/20 0.48
▸ PDE6D O43924 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.46
▸ LMNA P02545 2/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ ACE P12821 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL917602 0.83 CYP1A2 (0.55) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917600 0.83 CYP1A2 (0.55) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL2781005 0.83 CYP1A2 (0.55) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL7031256 0.78 MAPT (0.50) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917559 0.77 MAPT (0.55) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917556 0.77 MAPT (0.55) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL12938088 0.76 ALDH1A1 (0.65) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL12805765 0.73 ALDH1A1 (0.61) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL13086556 0.73 MAPT (0.64) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL6322887 0.73 ALDH1A1 (0.61) GALR3HTR4MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative H. LUNDBECK A/S (DK) 2004-06-10 — — US disclosed
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative H. LUNDBECK A/S (DK) 2004-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative GALR3, GALR2, GALR1 GALR3 1/4885HTR4 17/4885MAPT 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback